Physician profile
Mark R Lonquist
NPI 1629064613
$12,309.98
in general payments reported to CMS, 2019-2025
56 companies · $1,492 in 2025
The $1,492 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,654 · 2020: $2,122 · 2021: $1,425 · 2022: $1,826 · 2023: $1,471 · 2024: $1,320 · 2025: $1,492.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,283.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,282.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,870.15 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,252.16 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,180.03 | 2019-2025 | Jardiance |
| Glaxosmithkline, LLC. | $940.28 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $922.91 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Amgen INC. | $631.43 | 2019-2023 | Otezla, Repatha |
| Lilly USA, LLC | $577.18 | 2019-2025 | Mounjaro, Trulicity, Jardiance |
| Astellas Pharma US INC | $508.92 | 2019-2025 | Veozah, Myrbetriq |
| Janssen Pharmaceuticals, INC | $477.66 | 2019-2022 | |
| Pfizer INC. | $405.51 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $327.36 | 2019-2025 | Vaxneuvance, Gardasil 9, Capvaxive |
| Takeda Pharmaceuticals U.S.A., INC. | $290.77 | 2019-2023 | Trintellix |
| Daiichi Sankyo INC. | $280.01 | 2019-2021 | |
| Amarin Pharma, INC. | $248.38 | 2020-2022 | |
| Sanofi-Aventis U.S. LLC | $245.74 | 2019-2023 |
Show all 56 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Lonquist listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.